<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189799</url>
  </required_header>
  <id_info>
    <org_study_id>1K23DA020085</org_study_id>
    <nct_id>NCT01189799</nct_id>
  </id_info>
  <brief_title>Motivational Therapy for Substance Users With Depression</brief_title>
  <acronym>Aftercare</acronym>
  <official_title>Motivational Therapy for Substance Users With Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to test the incremental efficacy and outcomes of an&#xD;
      aftercare program of Cognitive Behavioral Therapy combined with motivational therapy (CBT-MT)&#xD;
      relative to treatment as usual (TAU) in improving depression, substance use, and healthcare&#xD;
      outcomes in a population with drug dependence and comorbid major depressive disorder (MDD).&#xD;
      The investigators expect that among drug-dependent patients with comorbid MDD, CBT-MT will&#xD;
      yield better clinical outcomes relative to TAU in reducing depressive symptoms and substance&#xD;
      use and improving healthcare outcomes during treatment.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. Test efficacy and outcomes of CBT-MT and TAU&#xD;
&#xD;
        2. Evaluate the differential effect of CBT-MT versus TAU on HIV-risk behavior of&#xD;
           participants,&#xD;
&#xD;
        3. To evaluate the impact of cognitive functioning on treatment retention and outcomes, and&#xD;
&#xD;
        4. To explore additional psychosocial, demographic, and diagnostic factors (e.g., age,&#xD;
           gender, education level, motivation for change, social support) that may be associated&#xD;
           with treatment outcome and retention in this high need population.&#xD;
&#xD;
      This study will include approximately 80 participants randomized to either 12 weeks of&#xD;
      motivational therapy or treatment as usual. Both treatments will meet once weekly for 60&#xD;
      minutes. Participants will be recruited from the Adult Partial Hospitalization program at&#xD;
      UCLA. During the active treatment phase, participants will attend clinic weekly for&#xD;
      collection of data and urine specimens.&#xD;
&#xD;
        1. For those randomly assigned to CBT-MT, they will meet with a therapist in a group format&#xD;
           for 60-minute sessions once weekly.&#xD;
&#xD;
           a. Each CBT-MT session will begin with 20 minutes of motivational therapy (MT), followed&#xD;
           by 40 minutes of CBT content.&#xD;
&#xD;
        2. Those randomly assigned to TAU, they will attend a weekly 60-minute Dual Recovery&#xD;
           Anonymous self-help group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Depression</condition>
  <condition>Substance Dependence</condition>
  <arm_group>
    <arm_group_label>Motivational Therapy Aftercare</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual Recovery Anonymous</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aftercare Treatment as Usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational therapy</intervention_name>
    <description>Twelve, 60 minute weekly structured manualized therapy sessions.</description>
    <arm_group_label>Motivational Therapy Aftercare</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dual Recovery Anonymous/Treatment as usual</intervention_name>
    <description>Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.</description>
    <arm_group_label>Dual Recovery Anonymous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 or over&#xD;
&#xD;
          2. DSM-IV diagnosis of Substance Dependence (cannabis, stimulant, opioid, or prescription&#xD;
             drug) or DSM-IV diagnosis of Alcohol Dependence and abuse of cannabis, stimulant,&#xD;
             opioid, or prescription drug&#xD;
&#xD;
          3. DSM-IV diagnosis of lifetime Major Depressive Disorder (MDD)&#xD;
&#xD;
          4. BDI-II score of 13 or greater&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of life threatening or unstable medical illness&#xD;
&#xD;
          2. Lack of proficiency in English&#xD;
&#xD;
          3. Current homelessness (unless residing in a recovery home for which contact information&#xD;
             can be provided)&#xD;
&#xD;
          4. Psychiatric symptoms warranting safety concerns or inpatient treatment, including&#xD;
             acute suicide risk&#xD;
&#xD;
          5. Present diagnosis of Bipolar Disorder, Schizophrenia, or Schizoaffective Disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Anne Bellows, MSW</last_name>
    <phone>310-267-5232</phone>
    <email>abellows@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Integrated Substance Abuse Programs</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Bellows, MSW</last_name>
      <phone>310-267-5232</phone>
      <email>abellows@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Suzette Glasner-Edwards, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>August 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2010</study_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Suzette Glasner Edwards, PhD</name_title>
    <organization>UCLA, Integrated Substance Abuse Programs</organization>
  </responsible_party>
  <keyword>Co-occurring Disorders</keyword>
  <keyword>Depression</keyword>
  <keyword>Substance Dependence</keyword>
  <keyword>Motivational Therapy</keyword>
  <keyword>Aftercare</keyword>
  <keyword>Cognitive Behavioral Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

